There was described amplification and maintenance of normal human hematopoietic stem cells induced by HDAC inhibitors [128], enhancement of the epithelial–mesenchymal transition of colorectal and breast cancer cells [129,130] and induction of CD133 (a marker of cancer stem cells in some cancers including the brain tumors) expression in human glioma [131]. Here, HDAC9 is linked to cancer.